GLP-1
Clinical Guide

Promotional access profile #2

SuperHealthy Rx Review

Which licensed professionals and written instructions apply to the treatment actually offered?

Published offer / checked November 13, 2026

November 13 snapshot: advertised semaglutide $85/month and tirzepatide $135/month; selected billing agreement unverified.

01 / Keep the offer date with the offer

November 13 Black Friday wording differs from the older record; later selected offers remain unverified. [November 13 source]

Earlier record · October 5, 2026

SuperHealthy Rx's retrieved offer lists compounded semaglutide at $85 monthly and tirzepatide at $135. The page still displayed Labor Day promotion language when checked October 5, 2026. Treat the figures as an observation from that page and confirm the actual checkout offer. We have not independently established when the promotion ends.

Service and payment update · October 10, 2026

Earlier service descriptions and their limits

The October 10 shipping and payment entries below remain historical advertising records. Customer-service speed and helpfulness have not been tested by this publication.

Use the published contact channel to ask about an order. A contact link is not evidence that a reply will be quick or resolve the issue. Contact SuperHealthy Rx.

Complimentary two-day shipping is part of the advertised offer for approved prescriptions. Clinical review and pharmacy preparation precede that fast transit service. See the advertised shipping service.

Review the proposed way to pay

SuperHealthy Rx supports Klarna and Affirm payment options, with HSA/FSA cards accepted for qualifying expenses. The selected financing agreement determines approval and repayment costs, while your benefit plan determines health-account expense eligibility.

See Affirm’s eligibility information and IRS guidance on eligible medical expenses.

02 / Separate the bundle from the decision

The November 13 page advertises the visit, medication and shipping without a membership fee. Its FAQ describes requesting refills through a portal and disabling auto-refill before an order. Selected billing frequency, term, renewal, cancellation and any early-termination charge are left to checkout, which we did not open. A refund is advertised when treatment is not prescribed; this is not an unconditional refund promise. [November 13 source]

Ask the service to identify the current setting on the proposed order rather than inferring it from the words “refill” or “no membership.” Keep the next charge, the action that prevents it and any already-processing order separate. Do not assume that a change to billing changes the clinical plan.

A useful written reply should identify the selected agreement and the question it answers. Save an unresolved item as unresolved: a seasonal headline, a portal instruction and an individual order confirmation are not interchangeable evidence. Confirm the clinician and pharmacy contacts separately from the billing contact.

03 / Ask for specific identities

The page refers to MD Integrations and U.S. licensed pharmacies. A network reference does not name the individual professional or pharmacy involved in your care. Ask for those details and the route for confirming the product label. FDA's concerns about unapproved GLP-1 products make precise identification more useful than a broad reassurance.

04 / Clarify the instruction pathway

Before using any prescribed product, establish where its instructions come from and who will resolve a discrepancy. A provider's advertisement should not be used as a dosing reference. Compounded medicines are not FDA-approved, and instructions for a different brand or presentation should not be assumed to apply.

The publisher selected SuperHealthy for promotional position two. Links may provide compensation. The Clinical Literacy Desk has not received care through the service or tested its clinical follow-up. Our role is to identify questions that make the public offer more understandable, while leaving individual medical decisions with the responsible licensed professional.

Source notes

Supplemental checks are dated November 13, 2026. Earlier records retain their original check dates; a new page edit does not refresh every source. Provider pages document advertised terms. Study summaries identify the scope of our review.

  1. SuperHealthy Rx — GLP-1 offerProvider promotion · Original check October 5, 2026
  2. FDA — compounding questions and answersCompounded-product context · Original check October 5, 2026
  3. FDA — concerns with unapproved GLP-1 productsMedication safety context · Checked 2026-10-21
  4. SuperHealthy Rx — November 13 offer and termsProvider promotion; checkout agreement not retrieved · Checked November 13, 2026

Return to the access comparison →